These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 38752577)
1. Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease. Haghdel A; Smith N; Glodzik L; Li Y; Wang X; Crowder T; Zhu YS; Butler T; Blennow K; McIntire LB; Pahlajani S; Osborne J; Chiang G; de Leon M; Ivanidze J Alzheimer Dis Assoc Disord; 2024 Apr-Jun 01; 38(2):107-111. PubMed ID: 38752577 [TBL] [Abstract][Full Text] [Related]
2. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes. Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722 [TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O; JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367 [TBL] [Abstract][Full Text] [Related]
5. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Miners JS; Kehoe PG; Love S; Zetterberg H; Blennow K Alzheimers Res Ther; 2019 Sep; 11(1):81. PubMed ID: 31521199 [TBL] [Abstract][Full Text] [Related]
7. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954 [TBL] [Abstract][Full Text] [Related]
8. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509 [TBL] [Abstract][Full Text] [Related]
9. Amyloid PETs are commonly negative in suspected Alzheimer's disease with an increase in CSF phosphorylated-tau protein concentration but an Aβ42 concentration in the very high range: a prospective study. Manca C; Rivasseau Jonveaux T; Roch V; Marie PY; Karcher G; Lamiral Z; Malaplate C; Verger A J Neurol; 2019 Jul; 266(7):1685-1692. PubMed ID: 30963253 [TBL] [Abstract][Full Text] [Related]
10. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences. de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058 [TBL] [Abstract][Full Text] [Related]
11. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545 [TBL] [Abstract][Full Text] [Related]
12. Assessing blood-brain barrier dysfunction and its association with Alzheimer's pathology, cognitive impairment and neuroinflammation. Preis L; Villringer K; Brosseron F; Düzel E; Jessen F; Petzold GC; Ramirez A; Spottke A; Fiebach JB; Peters O Alzheimers Res Ther; 2024 Jul; 16(1):172. PubMed ID: 39085945 [TBL] [Abstract][Full Text] [Related]
13. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease. Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028 [TBL] [Abstract][Full Text] [Related]
14. Characterization of Alzheimer Disease Biomarker Discrepancies Using Cerebrospinal Fluid Phosphorylated Tau and AV1451 Positron Emission Tomography. Meyer PF; Pichet Binette A; Gonneaud J; Breitner JCS; Villeneuve S JAMA Neurol; 2020 Apr; 77(4):508-516. PubMed ID: 31961372 [TBL] [Abstract][Full Text] [Related]
15. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311 [TBL] [Abstract][Full Text] [Related]
16. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds. Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503 [TBL] [Abstract][Full Text] [Related]
17. Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. Ali M; Sung YJ; Wang F; Fernández MV; Morris JC; Fagan AM; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleó A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Haass C; Ewers M; Levin J; Farlow MR; Perrin RJ; ; ; Cruchaga C PLoS One; 2022; 17(5):e0267298. PubMed ID: 35617280 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer's Disease. Kehoe PG; Al Mulhim N; Zetterberg H; Blennow K; Miners JS J Alzheimers Dis; 2019; 72(2):525-535. PubMed ID: 31594235 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]